Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients

Autor: Olivier Marion, MD, Arnaud Del Bello, MD, Florence Abravanel, PharmD, PhD, Stanislas Faguer, MD, PhD, Laure Esposito, MD, Anne Laure Hebral, MD, Julie Bellière, MD, PhD, Jacques Izopet, PharmD, PhD, Nassim Kamar, MD, PhD
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Transplantation Direct, Vol 8, Iss 1, p e1248 (2022)
Druh dokumentu: article
ISSN: 2373-8731
00000000
DOI: 10.1097/TXD.0000000000001248
Popis: Background. A weak immunogenicity has been reported in solid organ transplant (SOT) recipients after 2 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The aim of this retrospective study was to identify the predictive factors for humoral response in SOT patients. Methods. Three hundred and ninety-three SOT patients from our center with at least 4 wk of follow-up after 2 doses of mRNA-based vaccine were included in this study. Anti-SARS-Cov-2 spike protein antibodies were assessed before and after vaccination. Results. Anti-SARS-CoV-2 antibodies were detected in 34% of the patients: 33.7% of kidney transplant patients, 47.7% of liver transplant patients, and 14.3% of thoracic transplant patients (P = 0.005). Independent predictive factors for humoral response after vaccination were male gender, a longer period between transplantation and vaccination, liver transplant recipients, a higher lymphocyte count at baseline, a higher estimated glomerular filtration rate and receiving the tacrolimus + everolimus ± steroids combination. Conversely, the nondevelopment of anti-SARS-CoV-2 antibodies after vaccination was associated with younger patients, thoracic organ recipients, induction therapy recipients, and tacrolimus + mycophenolic acid ± steroids recipients. Conclusions. The immunosuppressive regimen is a modifiable predictive factor for humoral response to SARS-CoV-2 vaccine.
Databáze: Directory of Open Access Journals
Externí odkaz: